medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2018, Number S1

<< Back Next >>

Acta Pediatr Mex 2018; 39 (S1)

Challenges and opportunities in the implementation of the neonatal screening for cystic fibrosis

Ibarra-González I, Gutiérrez-Morales G, Vela-Amieva M, Castillo-Mogel JA, Herrera-Pérez LA, Caamal-Parra G, Herrera-Maldonado N, García-Flores EP

Language: Spanish
References: 41
Page: 35-46
PDF size: 649.25 Kb.


ABSTRACT

Introduction: Early detection of cystic fibrosis (CF) by newborn screening (NBS) has a positive effect on the clinical outcome of the disease however, its implementation is complex and there is no universal protocol. The quantification of immunoreactive trypsinogen (IRT) is used as initial biomarker of all current CF-NBS algorithms. OBJECTIVE: To present the preliminary results of the application of an algorithm for the NBS of CF in the Ministry of Health of Mexico.
Materials and Methods: Retrospective study of the results of the application of an algorithm consisting of IRT/IRT quantification followed by sweat test (ST) for the detection of CF in the NBS program of the Ministry of Health of Mexico.
Results: Filter paper blood samples were obtained from 1,273,727 newborns (NB), being 1,267,122 specimens suitable for biochemical processing; 3,216 samples showed IRT blood values above 95.5 percentile. Second IRT sample was obtained only in 54% suspicious NB. 1,787 ST were performed and 202 highly CF suggestive cases (1:6,273 NB) were detected and sent to medical follow-up. The high number of extemporaneous samples contributes significantly to the high number of ST. Our results allow us to identify the main difficulties of the CF NBS implementation using the IRT/IRT/ST algorithm.
Conclusion: The incorporation of this first NBS algorithm for CF detection in Mexico represents an achievement however, it is necessary to improve it.


REFERENCES

  1. Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Hum Mutat. 2002;19(6):575-606.

  2. Therrell BL, Hannon WH, Hoffman G, Ojodu J, Farrell PM. Immunoreactive trypsinogen (IRT) as a biomarker for cystic fibrosis: challenges in newborn dried blood spot screening. Mol Genet Metab 2012;106(1):1-6. doi: 10.1016/j. ymgme.2012.02.013.

  3. World Health Organization. The molecular genetic epidemiology of cystic fibrosis, http://www.who.int/genomics/ publications/en (2004, accessed 12 August 2017).

  4. Coffey MJ, Whitaker V, Gentin N, Junek R, Shalhoub C, Nightingale S, Hilton J, Wiley V, Wilcken B, Gaskin KJ, Ooi CY. Differences in Outcomes between Early and Late Diagnosis of Cystic Fibrosis in the Newborn Screening Era. J Pediatr. 2017;181:137-145.e1. doi: 10.1016/j.jpeds.2016.10.045.

  5. Kharrazi M, Yang J, Bishop T, Lessing S, Young S, Graham S, Pearl M, Chow H, Ho T, Currier R, Gaffney L, Feuchtbaum L; California Cystic Fibrosis Newborn Screening Consortium. Newborn screening for cystic fibrosis in California. Pediatrics 2015;136(6):1062-1072. doi: 10.1542/ peds.2015-0811.

  6. Vankeerberghen, A., Cuppens, H., & Cassiman, J.J. The cystic fibrosis transmembrane conductance regulator: An intriguing protein with pleiotropic functions. J Cyst Fibros, 2002;1(1):13-29. doi.org/10.1016/S1569-1993(01)00003-0

  7. De Rose V. Mechanisms and markers of airway inflammation in cystic fibrosis. Eur Respir J.2002;19(2):333-40. doi.org/10.1183/09031936.02.00229202

  8. Evans AK, Fitzgerald DA, McKay KO. The impact of meconium ileus on the clinical course of children with cystic fibrosis. Eur Respir J. 2001;18(5):784-9. doi.org/10.1016/ S1569-1993(07)60174-X.

  9. Paranjape, S. M., & Mogayzel, P. J. Cystic Fibrosis. Pediatr Rev 2014, 35(5):194-205. doi.org/10.1542/pir.35-5-194

  10. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005 12;352(19):1992-2001. doi.org/10.1007/978- 1-61779-120-8

  11. Castellani C, Massie J, Sontag M, Southern KW. Newborn screening for cystic fibrosis. Lancet Respir Med. 2016;4(8):653-661. doi: 10.1016/S2213-2600(16)00053-9.

  12. Rosenfeld M, Sontag MK, Ren CL. Cystic Fibrosis Diagnosis and Newborn Screening. Pediatr Clin North Am. 2016;63(4):599-615. doi: 10.1016/j.pcl.2016.04.004

  13. Balfour-Lynn IM Newborn screening for cystic fibrosis: evidence for benefit. Arch Dis Child. 2008;93(1):7-10.

  14. Tridello G, Castellani C, Meneghelli I, Tamanini A, Assael BM. Early diagnosis from newborn screening maximises survival in severe cystic fibrosis. ERJ Open Res. 2018 20;4(2). pii: 00109-2017. doi: 10.1183/23120541.00109- 2017

  15. Comeau AM1, Accurso FJ, White TB, Campbell PW 3rd, Hoffman G, Parad RB, Wilfond BS, Rosenfeld M, Sontag MK, Massie J, Farrell PM, O’Sullivan BP; Cystic Fibrosis Foundation. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics. 2007;119(2):e495-518.

  16. Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I, Southern KW, Marshall BC, Sosnay PR. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017;181S:S4-S15. e1. doi: 10.1016/j.jpeds.2016.09.064.

  17. Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodková P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153- 178. doi: 10.1016/j.jcf.2018.02.006.

  18. NHS Screening Programmes A Laboratory Guide to Newborn Screening in the UK for Cystic Fibrosis. Fourth Edition February 2014. www.newbornbloodspot.screening.nhs.uk

  19. Vernooij-van Langen A, Dompeling E, Yntema JB, Arets B, Tiddens H, Loeber G, Dankert-Roelse J. Clinical evaluation of the Nanoduct sweat test system in the diagnosis of cystic fibrosis after newborn screening. Eur J Pediatr. 2015;174(8):1025-34. doi: 10.1007/s00431-015-2501-0.

  20. Wiencek JR, Lo SF. Advances in the Diagnosis and Management of Cystic Fibrosis in the Genomic Era. Clin Chem. 2018 Jun;64(6):898-908. doi: 10.1373/clinchem.2017.274670.

  21. Ley General de Salud (2007). Disponible: http://www. salud.gob.mx/unidades/cdi/legis/lgs/index-indice.htm.

  22. Norma Técnica número 321 para la prevención del retraso mental producido por hipotiroidismo congénito. Diario Oficial de la Federación, 22/09/1988, México.

  23. Norma Oficial Mexicana NOM-034-SSA2-2013, Para la prevención y control de los defectos al nacimiento. Diario Oficial de la Federación, 24/06/2014, México.

  24. Norma Oficial Mexicana NOM-007-SSA2-2016, Para la atención de la mujer durante el embarazo, parto y puerperio, y de la persona recién nacida. Diario Oficial de la Federación, 01/04/2016, México.

  25. Vernooij-van Langen A, Dompeling E, Yntema JB, Arets B, Tiddens H, Loeber G, et al. Clinical evaluation of the Nanoduct sweat test system in the diagnosis of cystic fibrosis after newborn screening. Eur J Pediatr. 2015;174(8):1025- 34. doi: 10.1007/s00431-015-2501-0.

  26. Paz Valiñas L. Cribado neonatal de la fibrosis quística. Eficacia/efectividad y protocolos de implementación. Red Española de Agencias de Evaluación de Tecnologías y Prestaciones del SNS. Axencia de Avaliación de Tecnoloxías Sanitarias de Galicia; 2013. Informes de evaluación de tecnologías sanitarias.

  27. Sarles J, Giorgi R, Berthézène P, Munck A, Cheillan D, Dagorn JC, et al. Neonatal screening for cystic fibrosis: comparing the performances of IRT/DNA and IRT/PAP. J Cyst Fibros. 2014;13(4):384-90. doi: 10.1016/j.jcf.2014.01.004.

  28. Comeau AM, Parad R, Gerstle R, O’Sullivan BP, Dorkin HL, Dovey M et al. Challenges in implementing a successful newborn cystic fibrosis screening program. J Pediatr. 2005;147(3 Suppl):S89-93.

  29. Grosse SD. Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis. Healthcare (Basel). 2015;3(4):1133-57.

  30. Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJ, Adams J. Current status of newborn screening worldwide: 2015. Semin Perinatol. 2015;39(3):171-87. doi: 10.1053/j.semperi.2015.03.002.

  31. Therrell BL Jr, Padilla CD. Newborn screening in the developing countries. Curr Opin Pediatr. 2018. doi: 10.1097/ MOP.0000000000000683.

  32. Howson CP, Cedergren B, Giugliani R, Huhtinen P, Padilla CD, Palubiak CS, et al. Universal newborn screening: A roadmap for action. Mol Genet Metab. 2018;124(3):177-183. doi: 10.1016/j.ymgme.2018.04.009.

  33. Ibarra-González I, Campos-Garcia FJ, Herrera-Pérez LDA, Martínez-Cruz P, Moreno-Graciano CM, Contreras-Capetillo SN, León-Burgos V, Maldonado-Solis FA, Alcántara- Ortigoza MA, González Del Angel A, Vela-Amieva M. Newborn cystic fibrosis screening in southeastern Mexico: Birth prevalence and novel CFTR gene variants. J Med Screen. 2017;1:969141317722808. doi: 10.1177/0969141317722808.

  34. Cheillan D1, Vercherat M, Chevalier-Porst F, Charcosset M, Rolland MO, Dorche C. False-positive results in neonatal screening for cystic fibrosis based on a three-stage protocol (IRT/DNA/IRT): Should we adjust IRT cut-off to ethnic origin?. J Inherit Metab Dis. 2005;28(6):813-8.

  35. Rodrigues R1, Magalhaes PK, Fernandes MI, Gabetta CS, Ribeiro AF, Pedro KP, et al. Neonatal screening for cystic fibrosis in São Paulo State, Brazil: a pilot study. Braz J Med Biol Res. 2009;42(10):973-8.

  36. Lezana Fernández JL, Bustamante Sáenz A, Ovando Fonseca JE, Boites Velarde R, Ruiz Gutiérrez HH (Editores). Fibrosis Quística. Guías clínicas para el diagnóstico y tratamiento. Intersistemas Editores, México D.F., 2015, 2a edición. 156 pp.

  37. Hale JE, Parad RB, Dorkin HL, Gerstle R, Lapey A, O’Sullivan BP, et al. Cystic fibrosis newborn screening: using experience to optimize the screening algorithm. J Inherit Metab Dis. 2010;33(Suppl 2):S255-61. doi: 10.1007/s10545-010-9117-3

  38. Haute Autorité de Santé. Place de la stratégie couplant les dosages de la trypsine immunoréactive (TIR) et de la protéine associée à la pancréatite (PAP) dans le dépistage systématique de la mucoviscidose en France. Haute Autorité de Santé - Service évaluation économique et santé publique; 2015.https://www.has-sante.fr/portail/upload/ docs/application/pdf/2015-06/place_de_la_strategie_couplant_ les_dosages_de_la_tir_et_de_la_pap_dans_le_depistage_ systematique_de_la_mucoviscidose_en_france.pdf.

  39. Seror V, Cao C, Roussey M, Giorgi R. PAP assays in newborn screening for cystic fibrosis: a population-based cost-effectiveness study. J Med Screen 2016;23(2):62–9. https://doi. org/10.1177/0969141315599421.

  40. Dankert-Roelse JE, Bouva MJ, Jakobs BS, Janssens HM, de Winter-de Groot KM, Schönbeck Y, et al. Newborn blood spot screening for cystic fibrosis with a four-step screening strategy in the Netherlands.J Cyst Fibros. 2018 Aug 23. pii: S1569-1993(18)30705-7. doi:10.1016/j.jcf.2018.07.008.

  41. Sermet-Gaudelus I, Brouard J, Audrézet MP, Couderc Kohen L, Weiss L, Wizla N, et al. Guidelines for the clinical management and follow-up of infants with inconclusive cystic fibrosis diagnosis through newborn screening. Arch Pediatr. 2017;24(12):e1-e14. doi: 10.1016/j.arcped.2017.07.015.




2020     |     www.medigraphic.com